<DOC>
	<DOC>NCT01281553</DOC>
	<brief_summary>The purpose of this study is to compare the efficacy and tolerability of cisapride with placebo in infants and children with gastro-oesophageal reflux disease (GORD).</brief_summary>
	<brief_title>A Study of Cisapride in Patients With Symptomatic Gastro-Oesophageal Reflux Disease</brief_title>
	<detailed_description>This is a double-blind (neither patient nor study staff will know the identity of the assigned treatment) study evaluate the effectiveness and safety of cisapride in patients with gastro-oesophageal reflux disease (GORD) (also referred to as gastroesophageal reflux disease [GERD[) compared to a placebo (a identical in appearance to cisapride but does not contain active drug). Patients will receive placebo or cisapride suspension at 0.2 mg/kg (volumn determined by patient weight) four times per day (q.i.d.) (15 minutes before feeding 3 times a day and at bedtime) orally (by mouth) for 8 weeks.</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Cisapride</mesh_term>
	<criteria>Diagnosis of GORD based on protocolspecified characteristics Failed the 1st of 5 stepwise treatments for GORD recommended by the European Society of Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Caregiver able to complete the IGERQR questionnaire Protocolspecified respiratory conditions requiring previous or current treatment with oral or intravenous corticosteroids (prior and concurrent use of inhaled corticosteroids is acceptable) Cause of vomiting/regurgitation other than GORD Prior history of cisapride intake</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Cisapride (PREPULSID)</keyword>
	<keyword>Placebo</keyword>
	<keyword>Gastroesophageal Reflux Disease (GERD)</keyword>
	<keyword>Gastro-oesophageal Reflux Disease (GORD)</keyword>
</DOC>